
New drug launches face more marketplace scrutiny today than a decade ago. Brand success requires not only communicating the clinical value to providers and patients, but also demonstrating the cost-effectiveness to payers in a real-world setting.

Andy Pyfer is a partner at Fingerpaint.

New drug launches face more marketplace scrutiny today than a decade ago. Brand success requires not only communicating the clinical value to providers and patients, but also demonstrating the cost-effectiveness to payers in a real-world setting.

Published: April 30th 2020 | Updated: